In a resounding success, Lonza has secured its financial future by placing two tranches totaling CHF 400 million. The first tranche of CHF 185 million, featuring a 2.25% interest rate and maturing in 2028, was complemented by a second
In a groundbreaking move, Boehringer Ingelheim has sealed the deal to acquire T3 Pharmaceuticals, a dynamic Swiss biotech company, for a staggering amount of up to 450 million CHF. This strategic move signals a major leap
In a transaction that echoes the essence of refined heritage, Gérard and Nadia Dominicé have gracefully secured ownership of seven parcels in the picturesque commune of Genthod, nestled within the canton of Geneva. This
Baker McKenzie, with its teams in Singapore, Switzerland, and Japan, served as legal advisor to DBS Bank, UBS, and SBI Digital Asset Holdings in executing the world’s first cross-border repo and natively-issued digital bond
Waterland Private Equity, along with the minority stakeholders of Netrics Holding, has formalized a share purchase agreement for the divestment of all shares in Netrics Group to Bregal Unternehmerkapital, a global private equity firm. Netrics
Luzerner Kantonalbank acted as arranger, agent, security agent and lender, along with other Swiss and Liechtenstein banks as lender in connection with their EUR 150 million financing of GarLa AcquiCo and its subsidiaries, GarLa Group. The
Schellenberg Wittmer, led by partner Olivier Favre (pictured), provided legal support to the Swiss Bankers Association (SBA) for updating its definitions for interest rate products used in over-the-counter derivative transactions documented under the Swiss Master
Homburger provided legal counsel to Commerzbank Aktiengesellschaft for a syndicated corporate financing deal involving Montana Aerospace. This company is a well-known manufacturer of aerospace system components and complex assemblies, operating globally with development and production
Nouscom, a clinical stage immuno-oncology company developing off-the-shelf and personalized viral vector-based cancer vaccines targeting neoantigens, has announced the completion of its oversubscribed Series C equity financing raising EUR 67.5m (USD 72m) from a syndicate
LASCCO, a biomedical-technology company, and Abionic, a nanotechnology company, both based at the Biopôle of Lausanne, entered into a licensing agreement with Fapon Biotech, a global leading life sciences company, based in Dongguan (China)
